Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. https://doi.org/10.1067/mcp.2001.113989.

Article  Google Scholar 

Loder E, Rizzoli P. Biomarkers in migraine: their promise, problems, and practical applications. Headache. 2006;46(7):1046–58. https://doi.org/10.1111/j.1526-4610.2006.00498.x.

Article  PubMed  Google Scholar 

Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov. 2006;5(6):463–9. https://doi.org/10.1038/nrd2033.

Article  CAS  PubMed  Google Scholar 

Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache. 2013;53(8):1262–77. https://doi.org/10.1111/head.12174.

Article  PubMed  Google Scholar 

Headache Classification Committee of the International Headache Society (IHS) The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202.

Lipton RB, Chu MK. Conceptualizing the relationship between chronic migraine and episodic migraine. Expert Rev Neurother. 2009;9(10):1451–4. https://doi.org/10.1002/pmic.200800454.

Article  CAS  PubMed  Google Scholar 

Benatto MT, Florencio LL, Carvalho GF, Dach F, Bigal ME, Chaves TC, et al. Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. Arq Neuropsiquiatr. 2017;75(3):153–9. https://doi.org/10.1590/0004-282x20170015.

Article  PubMed  Google Scholar 

van Dongen RM, Zielman R, Noga M, Dekkers OM, Hankemeier T, van den Maagdenberg AM, et al. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia. 2017;37(1):49–63. https://doi.org/10.1177/0333102415625614.

Article  PubMed  Google Scholar 

Angioni D, Delrieu J, Hansson O, Fillit H, Aisen P, Cummings J, et al. Blood biomarkers from research use to clinical practice: what must be done? A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2022;9(4):569–79. https://doi.org/10.14283/jpad.2022.85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099–142. https://doi.org/10.1152/physrev.00034.2013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dos Santos JBR, da Silva MRR. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: a review. Eur J Pharmacol. 2022;922:174902. https://doi.org/10.1016/j.ejphar.2022.174902.

Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, et al. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22(1):128. https://doi.org/10.1186/s10194-021-01335-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56. https://doi.org/10.1002/ana.410330109.

Article  CAS  PubMed  Google Scholar 

Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–7. https://doi.org/10.1002/ana.410280213.

Article  CAS  PubMed  Google Scholar 

Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 2000;20(10):907–18. https://doi.org/10.1046/j.1468-2982.2000.00146.x.

Article  CAS  PubMed  Google Scholar 

Sarchielli P, Pini LA, Zanchin G, Alberti A, Maggioni F, Rossi C, et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia. 2006;26(3):257–65. https://doi.org/10.1111/j.1468-2982.2005.01016.x.

Article  CAS  PubMed  Google Scholar 

Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007;128(3):209–14. https://doi.org/10.1016/j.pain.2006.09.017.

Article  CAS  PubMed  Google Scholar 

Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000;86(1–2):133–8. https://doi.org/10.1016/s0304-3959(00)00232-3.

Article  CAS  PubMed  Google Scholar 

Ashina M, Hansen JM, BO ÁD, Olesen J. Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol. 2017;13(12):713–24. https://doi.org/10.1038/nrneurol.2017.137.

Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics Pain. 1989;38(1):17–24. https://doi.org/10.1016/0304-3959(89)90067-5.

Article  CAS  PubMed  Google Scholar 

Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15(5):384–90. https://doi.org/10.1046/j.1468-2982.1995.1505384.x.

Article  CAS  PubMed  Google Scholar 

Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106(3):461–70. https://doi.org/10.1016/j.pain.2003.09.008.

Article  CAS  PubMed  Google Scholar 

Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005;58(4):561–8. https://doi.org/10.1002/ana.20605.

Article  CAS  PubMed  Google Scholar 

Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P. Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks. Cephalalgia. 2022;42(3):186–96. https://doi.org/10.1177/03331024211040467.

Article  PubMed  Google Scholar 

Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R. Endothelial progenitor cells: a new key for endothelial dysfunction in migraine. Neurology. 2012;79(5):474–9. https://doi.org/10.1212/WNL.0b013e31826170ce.

Article  PubMed  Google Scholar 

Nicolodi M, Del Bianco E. Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache. Cephalalgia. 1990;10(1):39–50. https://doi.org/10.1046/j.1468-2982.1990.1001039.x.

Article  CAS  PubMed  Google Scholar 

Bellamy JL, Cady RK, Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache. 2006;46(1):24–33. https://doi.org/10.1111/j.1526-4610.2006.00294.x.

Article  PubMed  Google Scholar 

• Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia. 2019;39(12):1535–43. https://doi.org/10.1177/0333102419856640. An important study on the potential of blood CGRP levels as a marker of treatment effectiveness.

Cernuda-Morollón E, Martínez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine. Headache. 2014;54(6):987–95. https://doi.org/10.1111/head.12372.

Article  PubMed  Google Scholar 

•• Gárate G, González-Quintanilla V, González A, Pascual M, Pérez-Pereda S, Madera J, et al. Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol. 2023. https://doi.org/10.1002/ana.26658. An article on the use of blood CGRP levels as a marker of therapeutic response to treatment.

Article  PubMed  Google Scholar 

de Vries LS, Garrelds IM, Danser AHJ, Terwindt GM, MaassenVanDenBrink A. Serum CGRP in migraine patients using erenumab as preventive treatment. J Headache Pain. 2022;23(1):120. https://doi.org/10.1186/s10194-022-01483-z.

Article  CAS  Google Scholar 

Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25(3):179–83. https://doi.org/10.1111/j.1468-2982.2005.00836.x.

Article  CAS  PubMed  Google Scholar 

Nitecka-Buchta A, Marek B, Kapustecka JB, Baron S. Venopunction of the cubital vein as an alternative approach for CGRP plasma level evaluation in tmd patients. Endokrynol Pol. 2017;68(3):326–33. https://doi.org/10.5603/ep.2017.0025.

Article  CAS  PubMed  Google Scholar 

Messlinger K, Vogler B, Kuhn A, Sertel-Nakajima J, Frank F, Broessner G. CGRP measurements in human plasma - a methodological study. Cephalalgia. 2021;41(13):1359–73. https://doi.org/10.1177/03331024211024161.

Article  PubMed  PubMed Central  Google Scholar 

Vikelis M, Mitsikostas DD. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets. 2007;6(4):251–7. https://doi.org/10.2174/187152707781387279.

Article  CAS  PubMed  Google Scholar 

Ferrari MD, Odink J, Bos KD, Malessy MJ, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology. 1990;40(10):1582–6. https://doi.org/10.1212/wnl.40.10.1582.

Article  CAS  PubMed